Welcome to BARBRI, the trusted global leader in legal education. Continue to access the same expert-led Strafford CLE and CPE webinars you know and value. Plus, explore professional skills courses and more.
About the Course
Introduction
This CLE webinar will guide patent counsel on means-plus-function (MPF) claims and the USPTO's recent guidance. The panel will discuss the implications of the guidance for patent counsel and applicants. The panel will offer best practices to overcome the challenges of MPF claims and leverage 112(f) and functional claims.
Description
In March 2024, the USPTO issued guidance for examining patent claims with MPF and step-plus-function limitations under Section 112(f). The guidance discussed interpretation of MPF claims under Section 112(f), which permits drafters to "recite a function in a claim and rely on the specification for the corresponding structure, material, or acts that perform the function and equivalents to the disclosed structure, material, or acts."
The guidance instructs examiners to use a three-prong test to determine if Section 112(f) is involved. The guidance highlights claim interpretation and the importance of a clear record as well as the need to provide sufficient support to meet the requirements of definiteness, written description, and enablement.
Nearly all technological fields use MPF claiming. MPF claims can provide more protection for patent applicants than other claims. Counsel should keep in mind how claims are framed under Section 112(f), especially with MPF claims. It is essential for patent counsel to include adequate and precise descriptions in the patent specification to support the claimed functions.
Listen as our authoritative panel of patent attorneys examines MPF claims and the USPTO's recent guidance. The panel will discuss the implications of the guidance for patent counsel and applicants. The panel will offer best practices to overcome the challenges of MPF claims and leverage 112(f) and functional claims.
Presented By
Ms. Brougher is a patent attorney who focuses on all aspects of services related to patents in the areas of biotechnology, pharmaceuticals and medical devices, including patentability opinions, due diligence, patent drafting, domestic and foreign patent prosecution, development and management of patent portfolios, and general client counseling during all phases of a product’s lifecycle, from concept to commercialization. Her patent experience covers a variety of complex and innovative inventions involving small molecule drugs, biologics, cell-based technologies, compositions, drug formulations and drug delivery systems, immunotherapeutics, medical devices, diagnostic tests, nanotechnology, and immunology, particularly vaccines and antibodies. Ms. Brougher also has experience counseling clients on the Hatch-Waxman Act and is monitoring developments involving biosimilars under the Biologics Price Competition and Innovation Act.
Mr. Irving has more than 47 years of experience in the field of IP law. His practice includes due diligence, patent prosecution, reissue and reexamination, patent interferences, and counseling, including prelitigation, Orange Book listings of patents covering FDA-approved drugs, and infringement and validity analysis in the chemical fields, as well as litigation. Mr. Irving has served as lead counsel in many patent interferences.
Ms. O’Brien has more than 25 years of experience representing both domestic and foreign clients of all sizes in the areas of patent procurement, litigation, and client counseling, with a particular emphasis on chemical, biochemical, and pharmaceutical technologies. Exemplary areas of Ms. O’Brien’s technical expertise include polymer chemistry; ceramics; glass; food chemistry; cosmetics; paper products; adhesives; and pharmaceutical products including new chemical entities and formulations, as well as novel solid forms including polymorphs, cocrystals, and amorphous forms of compounds. Ms. O’Brien’s expertise includes all aspects of preparing and prosecuting U.S. and foreign patent applications, such as patent drafting and prosecution, as well as more complex matters such as reissue and reexamination proceedings, appeals hearings, Post-Grant Reviews (PGR), and Inter Partes Reviews (IPR) before the Patent Trial and Appeal Board (PTAB). Her litigation expertise focuses on patent infringement cases including, for example, Hatch-Waxman litigation involving Abbreviated New Drug Applications, and includes all stages from pre-discovery through trial.
-
This 90-minute webinar is eligible in most states for 1.5 CLE credits.
-
Live Online
On Demand
Date + Time
- event
Monday, May 20, 2024
- schedule
1:00 p.m. ET./10:00 a.m. PT
- MPF claims and the benefits of using them
- USPTO guidance
- Section 112(f) three-prong analysis
- Best practices
The panel will review these and other noteworthy issues:
- What are the benefits and limitations of using MPF patent claims?
- What are the potential implications of the USPTO's decision in Xencor?
- What are the alternatives if MPF is not available?
Unlimited access to premium CLE courses:
- Annual access
- Available live and on-demand
- Best for attorneys and legal professionals
Unlimited access to premium CPE courses.:
- Annual access
- Available live and on-demand
- Best for CPAs and tax professionals
Unlimited access to premium CLE, CPE, Professional Skills and Practice-Ready courses.:
- Annual access
- Available live and on-demand
- Best for legal, accounting, and tax professionals
Unlimited access to Professional Skills and Practice-Ready courses:
- Annual access
- Available on-demand
- Best for new attorneys
Related Courses
Advice of Counsel Defense in Patent Litigation and Protecting Attorney-Client Privilege
Thursday, April 16, 2026
1:00 p.m. ET./10:00 a.m. PT
EU Unitary Patent System and UPC: Recent Decisions and Developments
Tuesday, April 7, 2026
1:00 PM ET/10:00 AM PT